Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02818335 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3023414 Formulations and the Effect of Food
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02818335 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants.
The verdict
NCT02818335, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how much LY3023414 (a test formulation and a reference formulation) gets into the blood stream and how long it takes the body to get rid of it. The study will also evaluate the effects of a high fat meal on LY3023414 compared to taking LY3023414 on an empty stomach. In addition, the tolerability of the study drug formulations will be evaluated. Information about any side effects that may occur will be collected. This study includes 3 periods. Participants will be admitted to the clinical research unit (CRU) one day before dosing in each period. Total study duration is about 21 days, including follow-up. Screening may occur up to 30 days before the first dose of study drug. This study is for research purposes only and is not intended to treat any medical conditions.
Interventions
- DRUG LY3023414 Reference Fasted
- DRUG LY3023414 Test Fasted
- DRUG LY3023414 Test Fed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-07 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02818335
The ClinicalTrials.gov registry entry for NCT02818335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LY3023414 Reference Fasted is the first listed.
NCT02818335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02818335 about?
NCT02818335 is a clinical study titled "A Study of LY3023414 Formulations and the Effect of Food". The purpose of this study is to measure how much LY3023414 (a test formulation and a reference formulation) gets into the blood stream and how long it takes the body to get rid of it. The study will also evaluate the effects of a high fat meal on LY3023414 compared to taking LY3023414 on an empty s...
What is the current status of trial NCT02818335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-07. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02818335?
The interventions under investigation include: LY3023414 Reference Fasted (DRUG), LY3023414 Test Fasted (DRUG), LY3023414 Test Fed (DRUG).
Who is sponsoring clinical trial NCT02818335?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.